Breaking News Instant updates and real-time market news.

ALSK

Alaska Communications

$1.61

-0.015 (-0.92%)

, BZH

Beazer Homes

$10.81

0.19 (1.79%)

10:55
10/02/18
10/02
10:55
10/02/18
10:55

Deutsche Bank to hold a conference

26th Annual Leveraged Finance Conference will be held in Scottsdale, AZ on October 1-3 with webcasted company presentations to begin on October at 11 am; not all company presentations may be webcasted. Webcast Link

ALSK

Alaska Communications

$1.61

-0.015 (-0.92%)

BZH

Beazer Homes

$10.81

0.19 (1.79%)

ETM

Entercom

$7.41

-0.15 (-1.98%)

CLMT

Calumet Specialty Products

$6.30

-0.05 (-0.79%)

ERI

Eldorado Resorts

$49.19

0.57 (1.17%)

BHC

Bausch Health

$27.39

0.06 (0.22%)

TXMD

TherapeuticsMD

$5.99

0.11 (1.87%)

WSC

WillScot

$17.81

-0.135 (-0.75%)

BCO

Brink's

$69.08

-0.11 (-0.16%)

TTMI

TTM Technologies

$15.74

-0.02 (-0.13%)

CHTR

Charter

$322.50

1.22 (0.38%)

S

Sprint

$6.55

-0.005 (-0.08%)

SBGI

Sinclair Broadcast

$28.22

0.21 (0.75%)

CCOI

Cogent

$55.44

0.03 (0.05%)

WTW

Weight Watchers

$73.94

1.22 (1.68%)

CRY

CryoLife

$33.64

-0.385 (-1.13%)

  • 02

    Oct

  • 04

    Oct

  • 04

    Oct

  • 04

    Oct

  • 04

    Oct

  • 08

    Oct

  • 08

    Oct

  • 26

    Oct

  • 28

    Oct

  • 12

    Nov

  • 13

    Nov

  • 27

    Nov

  • 15

    Feb

  • 25

    Feb

ALSK Alaska Communications
$1.61

-0.015 (-0.92%)

BZH Beazer Homes
$10.81

0.19 (1.79%)

02/12/18
02/12/18
UPGRADE

Market Perform
Beazer Homes upgraded to Market Perform at JMP Securities
As previously reported, JMP Securities analyst Peter Martin upgraded Beazer Homes to Market Perform from Underperform, as he sees limited upside due to leverage and the company's land, labor, and material cost headwinds. Martin maintained his FY18 and FY19 estimates for Beazer, saying he believes the Orlando Gathering project will experience lower than average absorptions following two recent visits to the community.
02/13/18
02/13/18
UPGRADE
Target $22

Outperform
Beazer Homes upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Jay McCanless upgraded Beazer Homes to Outperform from Neutral with a $22 price target. Noting the stock price has declined about 17% year to date, the analyst argues that the magnitude of this decline is overdone since demand is rising for Beazer Homes' core entry-level product, and the company has essentially achieved its longer-term growth targets.
02/13/18
WEDB
02/13/18
UPGRADE
WEDB
Outperform
Beazer Homes upgraded to Outperform from Neutral at Wedbush
09/21/18
JPMS
09/21/18
DOWNGRADE
Target $13
JPMS
Neutral
Beazer Homes downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Rehaut downgraded Beazer Homes to Neutral and lowered his price target for the shares to $13 from $18. The analyst says that while the company's relative valuation is attractive, its operating margins are below average.
ETM Entercom
$7.41

-0.15 (-1.98%)

06/04/18
SPHN
06/04/18
NO CHANGE
Target $8
SPHN
Equal Weight
Entercom price target lowered to $8 from $12 at Stephens
Stephens analyst Kyle Evans noted that Entercom is down over 33% since reporting Q1 results and he expects the stock will "stay in the penalty box" until management produces materially better revenue trends. He lowered his price target on the stock to $8 from $12 and keeps an Equal Weight rating on Entercom.
05/09/18
NBLE
05/09/18
DOWNGRADE
NBLE
Hold
Entercom downgraded to Hold from Buy at Noble Financial
CLMT Calumet Specialty Products
$6.30

-0.05 (-0.79%)

12/29/17
WELS
12/29/17
NO CHANGE
Target $10
WELS
Outperform
Calumet Specialty Products restructuring remains on track, says Wells Fargo
Wells Fargo analyst Roger Read says Calumet Specialty Products' Q3 results yesterday were weaker than expected as hurricane impacts hurt Specialty Products more than they lifted Fuels' results. The quarter "represented one of those one step backwards amid many forward steps over the prior and coming quarters," Read tells investors in a post-earnings research note. Investors should be disappointed by the weaker results, "but the bigger picture should dominate," the analyst adds. He believes Calumet's restructuring remains on track and that near-term liquidity concerns "have evaporated" following the sale of its Superior refinery and Anchor Drilling Fluids operations. Read reiterates an Outperform rating on the shares with a $10 price target.
03/08/18
03/08/18
NO CHANGE

Calumet Specialty Products calls for redemption of 11.5% Senior Secured Notes
Calumet Specialty Products and its wholly owned subsidiary Calumet Finance have called for redemption of all of the $400M aggregate principal amount of their outstanding 11.5% Senior Secured Notes due 2021. The Partnership expects the redemption to be completed on April 9, and holders will receive a redemption price of 100.0% of the principal amount thereof, plus accrued and unpaid interest thereon up to, but not including, the Redemption Date, plus a Make Whole Premium. Additionally, the Partnership reached an agreement with its lenders for the renewal of its corporate revolving credit facility under a new five-year term.
ERI Eldorado Resorts
$49.19

0.57 (1.17%)

10/02/18
JPMS
10/02/18
NO CHANGE
Target $60
JPMS
Overweight
Eldorado Resorts price target raised to $60 from $56 at JPMorgan
JPMorgan analyst Daniel Politzer raised his price target for Eldorado Resorts to $60 to reflect the close of the Tropicana Entertainment acquisition. The analyst assumes Eldorado can generate a "reasonable" $80M of Tropicana-related synergies by 2020 versus the company's $40M target. He keeps an Overweight rating on the shares.
10/01/18
RHCO
10/01/18
INITIATION
Target $55
RHCO
Buy
Eldorado Resorts assumed with a Buy at SunTrust
SunTrust analyst Barry Jonas assumed Eldorado Resorts with a Buy rating and a price target of $55 as part of his broader "U.S. Gaming" coverage transfer research report. The analyst is positive on the company's shareholder value creation through M&A and believes that consensus does not fully reflect the management's ability to exceed guidance thanks to the recently announced JV created with William Hill.
06/12/18
ROTH
06/12/18
NO CHANGE
Target $60
ROTH
Buy
Eldorado Resorts price target raised to $60 from $56 at Roth Capital
Roth Capital analyst David Bain raised his price target for Eldorado Resorts to $60 from $56, while reiterating a Buy rating on the shares. The analyst believes there is a solid investment case for about $108 per share value based on reasonable CY21 operational and valuation assumptions. Further, Bain believes there is a strong possibility the company will announce another large-scale accretive acquisition within the next 18 to 24-months.
05/14/18
JEFF
05/14/18
NO CHANGE
JEFF
Jefferies says Penn National, Caesars among winners from sports gaming ruling
After the Supreme Court ruled that the PASPA provision prohibiting state authorization of organized sports gambling violates the tenth amendment, Jefferies analyst David Katz reiterated his view on which companies are positioned to be key beneficiaries of the decision. He continues to identify Penn National (PENN) and Caesars (CSR) as among the top winners in terms of casino operators, followed by Eldorado Resorts (ERI), Churchill Downs (CHDN), Boyd Gaming (BYD), Monarch Casino (MCRI), and MGM Resorts (MGM). He also sees "location-agnostic" suppliers Scientific Games (SGMS) and International Game (IGT) as winners, Katz tells investors.
BHC Bausch Health
$27.39

0.06 (0.22%)

09/17/18
09/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Reliance Steel (RS) initiated with a Neutral at Citi. 2. Bausch Health (BHC) assumed with an Overweight at Barclays. 3. Stanley Black & Decker (SWK) initiated with an Outperform at Credit Suisse. 4. Aramark (ARMK) initiated with an Outperform at Bernstein. 5. Kraft Heinz (KHC) was assumed with an Underweight at Morgan Stanley, while Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) were assumed with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
LEHM
09/17/18
INITIATION
Target $29
LEHM
Overweight
Bausch Health assumed with an Overweight at Barclays
Barclays analyst Geoff Meacham assumed coverage of Bausch Health Companies with an Overweight rating and $29 price target.
09/13/18
JEFF
09/13/18
NO CHANGE
Target $27
JEFF
Buy
Bausch bankruptcy risk arguably off table with settlement, says Jefferies
Bausch Health (BHC) yesterday announced an important settlement for Xifaxan with first to file Teva (TEVA), allowing for generic entry in January of 2028, Jefferies analyst David Steinberg tells investors in a research note. One could argue the settlement takes Bausch's bankruptcy risk off the table given the "long runway and greater certainty to future cash flows" from what is the company's most important drug, the analyst contends. Further, the deal could also allow the company to refinance its debt at more attractive terms. Steinberg keeps a Buy rating on Bausch Health with a $27 price target.
09/13/18
HCWC
09/13/18
NO CHANGE
Target $25
HCWC
Neutral
Bausch Health price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Bausch Health (BHC) to $25 after the company reached an agreement to resolve the outstanding intellectual property litigation regarding Xifaxan with Teva's (TEVA) Actavis Laboratories. While the analyst is "enthused" by the agreement, particularly since Actavis was the only entity to have received tentative approval of a generic rifaximin product, he notes that the competitive risks to Xifaxan "are not all in the rear view mirror quite yet." Other factors still remain to be clarified, including the status of the new drug application for Cosmo Pharmaceuticals' Rifamycin, which has an approval decision date of November 16, the analyst adds. Selvaraju keeps a Neutral rating on Bausch Health.
TXMD TherapeuticsMD
$5.99

0.11 (1.87%)

06/15/18
JPMS
06/15/18
INITIATION
Target $11
JPMS
Overweight
TherapeuticsMD initiated with an Overweight at JPMorgan
JPMorgan analyst Chris Schott started TherapeuticsMD with an Overweight rating and $11 price target. The analyst believes TX-001 and Imvexxy represent "significant" long-term opportunities. He sees peak sales of $750M for TX-001 and thinks Imvexxy can gain 20%-plus of the severe dyspareunia market over time. Schott sees TherapeuticsMD as well positioned in the women's health space.
08/14/18
CANT
08/14/18
NO CHANGE
Target $27
CANT
Overweight
Cantor raises TherapeuticsMD target to $27 on Annovera approval
Cantor Fitzgerald analyst William Tanner raised his price target for TherapeuticsMD to $27 from $26 following the approval of Annovera, which he says "provides another leg to the TXMD stool." The company's acquisition of commercial rights to Annovera should appeal to investors, Tanner tells investors in a research note. He believes the product is "clearly complementary" to the emerging women's health franchise. The analyst thinks he next 12-18 months could be a period of positive stock performance if TherapeuticsMD executes on the commercial front.
08/23/18
STFL
08/23/18
NO CHANGE
Target $20
STFL
Buy
TherapeuticsMD a 'rare early commercial story' in womens health, says Stifel
Stifel analyst Annabel Samimy kept her Buy rating and $20 price target on TherapeuticsMD, saying her recent meetings with the management focused on its launch of Imvexxy for VVA. The analyst notes that its early metrics are strong with over 2.4K prescriptions filled within weeks, adding that the product has "multiple ways to win" thanks to its win-affordability, education, and superiority.
06/08/18
CANT
06/08/18
NO CHANGE
Target $26
CANT
Overweight
TherapeuticsMD shares do not reflect value of Imvexxy, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views the recent FDA approval of Imvexxy as a major milestone for TherapeuticsMD that sets the company on a course to achieve long-term commercial viability. He reiterates an Overweight rating on the shares with a $26 price target. The investability of TherapeuticsMD stock "has increased considerably," Tanner tells investors in a research note. He believes the current stock price does not fully reflect the value of Imvexxy, "much less that of TX-001."
WSC WillScot
$17.81

-0.135 (-0.75%)

10/02/18
10/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. WillScot (WSC) initiated with a Buy at Deutsche Bank. 2. Scientific Games (SGMS) initiated with a Buy at SunTrust. 3. Omega Healthcare (OHI) initiated with a Neutral at MUFG. 4. BJ's Wholesale (BJ) resumed with a Buy at Citi. 5. Matthews (MATW) initiated with a Buy at Buckingham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/18
DBAB
10/01/18
INITIATION
Target $22
DBAB
Buy
WillScot initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Ashish Sabadra started WillScot with a Buy rating and $22 price target. The company, as a leading provider of modular spaces and mobile storage solutions, has a recurring revenue model with diverse end markets, a comprehensive offering, and dominant market share, Sabadra tells investors in a research note. Further, the analyst believes "robust" economic conditions are driving construction activity, which, along with recent hurricanes, should provide a multi-year utilization gain opportunity for WillScot.
10/01/18
10/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. KEYW (KEYW) initiated with an Outperform at William Blair. 2. Garrett Motion (GTX) initiated with an Underperform at RBC Capital. 3. WillScot (WSC) initiated with an Overweight at Morgan Stanley. 4. Bitauto (BITA) resumed with a Hold at 86 Research. 5. SB One Bancorp (SBBX) initiated with an Outperform at Boenning & Scattergood. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/18
MSCO
10/01/18
INITIATION
Target $21
MSCO
Overweight
WillScot initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Courtney Yakavonis started WillScot with an Overweight rating and $21 price target, calling the company the "clear market leader" in the highly fragmented modular space and portable storage rental market. WillScot has high visibility into near-to-medium term revenues due to its 3-year lease terms while also having additional M&A opportunities in the current mid-to-late construction cycle, Yakavonis tells investors.
BCO Brink's
$69.08

-0.11 (-0.16%)

05/31/18
BUCK
05/31/18
NO CHANGE
Target $110
BUCK
Buy
Brink's price target raised to $110 from $100 at Buckingham
Buckingham analyst James Clement raised his price target for Brink's to $110 after the company announced the acquisition of Dunbar. Dunbar is "geographically strong on the east coast and has done a great job of marketing to middle-market retailers and financial institutions," Clement tells investors in a research note. The analyst increased his 2019 earnings per share estimate for Brink's to $5.14 from $4.79 and keeps a Buy rating on the shares.
09/12/18
IMPC
09/12/18
NO CHANGE
Target $100
IMPC
Outperform
Brink's shares 'highly attractive' despite estimate cuts, says Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his earnings estimates for The Brink's Company to account for the recent devaluation of the Argentine peso, but the analyst keeps an Outperform rating on the shares with a $100 price target. The analyst reduced his estimates for South America due to continued weakness in the Argentine peso, which dropped his 2018 earnings per share estimate to $3.33 from $3.78 and 2019 estimate to $4.88 from $5.30. The Argentine peso fell 35% in Q2 and after six weeks of relative stability since late August, the peso plummeted another 39% against the dollar after the country's president, Mauricio Macri, asked the International Monetary Fund for $50B, Kessler tells investors in a research note. The analyst, however, continues to view Brink's shares as "highly attractive."
09/12/18
BREN
09/12/18
INITIATION
Target $90
BREN
Buy
Brink's initiated with a Buy at Berenberg
Berenberg started Brink's with a Buy rating and $90 price target.
03/26/18
BUCK
03/26/18
INITIATION
Target $100
BUCK
Buy
Brink's initiated with a Buy at Buckingham
Buckingham initiated Brink's with a Buy and $100 price target.
TTMI TTM Technologies
$15.74

-0.02 (-0.13%)

01/24/18
JPMS
01/24/18
NO CHANGE
JPMS
JPMorgan names top long ideas for 2018 in Applied Tech Hardware
JPMorgan analyst Paul Coster believes Applied Tech Hardware stocks are positioned to post solid returns in 2018 owing to cyclical tailwinds and attractive relative valuations. The analyst favors electronic manufacturing solutions stocks in particular give their unit-driven exposure to Internet of Things device proliferation across verticals. His top long ideas for 2018 are Flex (FLEX), NCR Corp. (NCR), TTM Technologies (TTMI) and Zebra Technologies (ZBRA).
12/14/17
RHCO
12/14/17
INITIATION
Target $20
RHCO
Buy
TTM Technologies initiated with a Buy at SunTrust
SunTrust analyst William Stein initiated TTM Technologies with a Buy rating and a price target of $20. Stein says the company's run of acquisitions has made it the world's third largest manufacturer of printed circuit boards, creating a more stable business model. The analyst expects future acquisitions to further accelerate sales growth and boost margins.
06/14/18
DBAB
06/14/18
INITIATION
Target $19
DBAB
Hold
TTM Technologies initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Sherri Scribner started TTM Technologies with a Hold rating and $19 price target. The analyst believes the shares are fairly valued at current levels. She expects slower growth in TTM's more mature segments like networking, communications, servers and storage to limit the stock's upside.
02/08/18
JPMS
02/08/18
NO CHANGE
Target $20
JPMS
Overweight
TTM Technologies removed from Analyst Focus List at JPMorgan
JPMorgan analyst Paul Coster removed TTM Technologies from his firm's Analyst Focus List after the company's Q1 earnings outlook missed expectations. The analyst views TTM as more of a second half of the year story and lowered his price target for the shares to $20 from $22. Coster reiterates an Overweight rating on the stock "with conviction," however. He notes the company continues to anticipate growth in Autos from higher content/vehicle and more customer engagements.
CHTR Charter
$322.50

1.22 (0.38%)

07/30/18
BUCK
07/30/18
NO CHANGE
Target $397
BUCK
Buy
Forced sale of Charter's New York assets seems unlikely, says Buckingham
Buckingham analyst Matthew Harrigan noted that New York's Public Service Commission has moved to push Charter out of the state and presented the company with a 60 day ultimatum to find a buyer for its assets there due to what it views as "repeated failures" to honor its commitments around the 2016 merger with Time Warner Cable. While he thinks an extended court battle seems "virtually certain," Harrigan does not see much likelihood of any forced disposition of its New York State assets. He keeps a Buy rating and $397 price target on Charter shares.
07/24/18
MKMP
07/24/18
NO CHANGE
Target $10
MKMP
Neutral
Infinera price target lowered to $10 from $12.50 at MKM Partners
MKM Partners analyst Michael Genovese lowered his price target on Infinera (INFN) to $10 and kept his Neutral rating after its $430M purchase of Coriant, saying the company believes that integration of key Optical and DSP technology will give it a competitive advantages. He also believes the deal "is a significant headwind for Acacia (ACIA) "since Infinera will look to move Coriant to its own vertically integrated technology platform". The analyst further notes that while Infinera preannounced Q2, the absence of Q3 guidance accompanying the deal suggests that the outlook may be at risk from reduced Charter Communications (CHTR) sales. Genovese concludes that Infinera may struggle to make up the 14% related revenue headwind to generate "flat to slightly up" Q3 sales.
07/30/18
07/30/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA UPGRADES AT&T TO BUY: Bank of America Merrill Lynch upgraded AT&T (T) to Buy from Neutral as analyst David Barden is positive on AT&T's 20-year low P/E multiple, Timer Warner merger benefits, favorable emerging wireless business trends, and a call option on value extraction from the merger of AT&T's distribution network with Time Warner's content and ad inventory. He keeps a $37 price target on AT&T shares. DEUTSCHE UPS JUNIPER IN 'CONTRARIAN' CALL: Deutsche Bank analyst Vijay Bhagavath upgraded Juniper Networks (JNPR) to Buy from Hold and raised his price target for the shares to $32 from $25. The analyst said he's "going against the grain" and making a "contrarian call." The post-earnings selloff on the "better than feared" Q2 results and below consensus Q3 guidance, which is primarily related to switch router upgrade timing at a handful of cloud and service provider customers, provides a "reasonable entry point." He believes "robust" switch router and next generation security refresh cycles will start in fiscal 2019 and that Juniper's fundamentals will improve from FY19 through FY21. STIFEL CUTS SYNCHRONOS TO SELL: Stifel analyst Tom Roderick downgraded Synchronoss (SNCR) to Sell from Hold, stating that recent filings reveal that liquidity issues loom, the company is "out of levers, and time is not on their side." The turnaround required to keep the company from fundraising "feels Herculean," added Roderick, who lowered his price target on Synchronoss shares to $3 from $8. BUCKINGHAM SAYS FORCED SALE OF CHARTER ASSETS 'UNLIKELY': Buckingham analyst Matthew Harrigan noted that New York's Public Service Commission has moved to push Charter (CHTR) out of the state and presented the company with a 60 day ultimatum to find a buyer for its assets there due to what it views as "repeated failures" to honor its commitments around the 2016 merger with Time Warner Cable. While he thinks an extended court battle seems "virtually certain," Harrigan does not see much likelihood of any forced disposition of its New York State assets. He keeps a Buy rating and $397 price target on Charter shares.
08/02/18
RILY
08/02/18
NO CHANGE
Target $62
RILY
Buy
GCI Liberty price target lowered to $62 from $70 at B. Riley FBR
B. Riley FBR analyst Barton Crockett lowered his price target for GCI Liberty (GLIBA) to $62 after updating his sum-of-the-parts analysis. The analyst still sees potential upside of 30%-plus, likely realized over next couple years via a merger with Charter Communications (CHTR). Charter is likely interested in GCI Liberty because of its holdings of Charter-related equity and its Alaskan cable business, Crockett tells investors in a research note. He keeps a Buy rating on GCI.
S Sprint
$6.55

-0.005 (-0.08%)

08/07/18
SBSH
08/07/18
NO CHANGE
SBSH
Citi credit sees 80% chance of T-Mobile, Sprint merger approval
Citi credit analyst David Phipps believes T-Mobile (TMUS) and Sprint (S) have an 80% chance of winning approval for their proposed merger. The market regularly puts merger approval odds at 50/50, Phipps tells investors in a fixed income research note. The analyst remains bullish on Sprint credit.
09/13/18
RILY
09/13/18
INITIATION
Target $46
RILY
Buy
Shenandoah initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Zack Silver started Shenandoah Telecommunications (SHEN) with a Buy rating and $46 price target. The analyst sees the company benefiting from the merger between Sprint (S) and T-Mobile (TMUS).
09/25/18
OPCO
09/25/18
NO CHANGE
Target $24
OPCO
Outperform
CenturyLink CFO departure raises concerns, says Oppenheimer
Oppenheimer analyst Timothy Horan notes CenturyLink (CTL) has announced that CFO Sunit Patel will depart as of September 28th to join T-Mobile (TMUS) to lead the Sprint (S)/T-Mobile merger and integration efforts. The analyst expects weakness in CenturyLink's stock, as investors will likely be concerned with synergy realization after Patel's departure. While Horan says his departure is disappointing, he believes CenturyLink has a deep management bench, and Jeff Storey, CEO, will continue to be the driving force behind restructuring and expense reductions at the company. He reiterates an Outperform rating and $24 price target on the shares.
06/28/18
06/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Air Transport Services (ATSG) upgraded to Buy from Hold at Stifel with analyst David Ross saying shares are attractive at current levels given long-term growth prospects. 2. T-Mobile (TMUS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche stating that recent conversations with some of his DC contacts have made him more optimistic that a deal to merge with Sprint (S) could be approved. 3. Talend (TLND) upgraded to Buy from Neutral at with analyst Tyler Radke saying a survey of Chief Data Officers shows "strong spending signals" while the company's competitive backdrop is favorable amid "increasing cloud tailwinds". 4. Regions Financial (RF) upgraded to Neutral from Underperform at Baird with analyst David George citing the recent pullback, which he thinks has made the valuation more reasonable. 5. Twilio (TWLO) upgraded to Buy from Hold at Argus with analyst Jim Kelleher saying the pullback in the stock price has created a more favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SBGI Sinclair Broadcast
$28.22

0.21 (0.75%)

09/06/18
RILY
09/06/18
DOWNGRADE
Target $33
RILY
Neutral
B. Riley FBR sees Sinclair in 'penalty box with sellers,' downgrades to Neutral
B. Riley FBR analyst Barton Crockett downgraded Sinclair Broadcast (SBGI) to Neutral from Buy and lowered his price target for the shares to $33 from $36. The $1B share buyback following the collapse of the Tribune Media (TRCO) deal is offset by Sinclair "being in a penalty box with sellers," Crockett tells investors in a research note. He believes the company is unlikely to participate in an "attractive wave of mergers sweeping the TV station group." Further, the analyst also sees some risk that Tribune prevails in its $1B lawsuit against Sinclair over the failed merger.
09/26/18
JPMS
09/26/18
INITIATION
Target $32
JPMS
Neutral
Sinclair Broadcast reinstated with a Neutral at JPMorgan
JPMorgan analyst Alexia Quadrani reinstated coverage of Sinclair Broadcast with a Neutral rating and $32 price target following a period of restriction. The analyst, who views the current valuation as "cheap," believes other broadcast groups offer better investment opportunities.
09/06/18
RILY
09/06/18
DOWNGRADE
Target $33
RILY
Neutral
Sinclair Broadcast downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Barton Crockett downgraded Sinclair Broadcast (SBGI) to Neutral and lowered his price target for the shares to $33 from $36. The analyst also raised his price target for Buy-rated Nexstar Media Group (NXST) to $92 from $87.
07/31/18
EVER
07/31/18
INITIATION
Target $34
EVER
In Line
Sinclair Broadcast initiated with an In Line at Evercore ISI
Evercore ISI analyst David Joyce initiated Sinclair Broadcast with an In Line and $34 price target.
CCOI Cogent
$55.44

0.03 (0.05%)

06/11/18
OPCO
06/11/18
NO CHANGE
Target $57
OPCO
Outperform
Cogent price target raised to $57 from $51 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for Cogent to $57 from $51 as he believes the company benefits from better overall IP transit volumes from improved OTT and share gains. The analyst thinks Cogent will see volume growth above 40% this year and 50% next year, which could drive revenue growth above 10% and EBITDA margin expansion above 150 bps per year. Horan reiterates an Outperform rating on the shares.
05/29/18
RBCM
05/29/18
DOWNGRADE
Target $51
RBCM
Sector Perform
Cogent downgraded to Sector Perform at RBC Capital on valuation
As reported earlier, RBC Capital analyst Kenneth Lee downgraded Cogent to Sector Perform from Outperform but raised his price target to $51 from $46. The analyst says the move to the sidelines is warranted by the limited potential return for the stock based on his new pricing model as well as the company trading at a premium on a relative historical basis. Lee adds that there is a "lack of foreseeable catalysts" that may drive estimates higher.
05/29/18
RBCM
05/29/18
DOWNGRADE
RBCM
Sector Perform
Cogent downgraded to Sector Perform from Outperform at RBC Capital
08/03/18
DBAB
08/03/18
NO CHANGE
DBAB
Deutsche closes short-term sell call on Cogent shares
Deutsche Bank analyst Matthew Niknam closed his short-term sell call on Cogent Communications shares citing the stock's recent underperformance. The analyst believes incremental downside to Cogent shares may be limited from current levels.
WTW Weight Watchers
$73.94

1.22 (1.68%)

09/13/18
09/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Equal Weight at Morgan Stanley. 2. AMSC (AMSC) initiated with a Buy at Craig-Hallum. 3. AudioEye (AEYE) initiated with a Buy at B. Riley FBR. 4. Lamar Advertising (LAMR) initiated with an Outperform at Imperial Capital. 5. Dicerna (DRNA) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/18
JPMS
10/02/18
NO CHANGE
Target $120
JPMS
Overweight
Weight Watchers added to America's Analyst Focus at JPMorgan
JPMorgan analyst Christina Brathwaite added Weight Watchers International to her firm's America's Analyst Focus while keeping an Overweight rating on the shares with a $120 price target. The stock's 30% pullback from its peak on June 20 presents a "compelling entry point for investors who missed the stock's appreciation the first time around," Brathwaite tells investors in a research note. Despite the post-earnings selloff, the analyst believes the Q2 print was actually indicative that Weight Watchers' growth story remains on track. Further, she believes the changes announced last week, including its new rewards program, as well as the company's Invite a Friend program, will help drive member recruitment and retention going forward.
09/17/18
CHLM
09/17/18
NO CHANGE
Target $120
CHLM
Buy
Weight Watchers' refresh could be 'major' positive catalyst, says Craig-Hallum
Craig-Hallum analyst Alex Fuhrman reiterated a Buy rating and $120 price target on Weight Watchers. In a research note to investors, the analyst says he believes the upcoming Weight Watchers brand refresh, which is expected to be unveiled before the end of the year and possibly before the early-November Q3 report, could be a major positive catalyst for shares. Fuhrman says Weight Watchers' brick and mortar locations could be rebranded as "WW Studio," which he calls a "significant upgrade" from the current "meetings" offering and sees the likely renaming of the "OnlinePlus" offering and the corporate wellness offering. Additionally, Fuhrman expects that the company's "underutilized" B&M locations may be put to more use, including possibly introducing regular operating hours for some of its higher-traffic locations.
09/14/18
DADA
09/14/18
NO CHANGE
DADA
Neutral
Nutrisystem more likely than public peers to buy Jenny Craig, says DA Davidson
After The Wall Street Journal recently reported that private equity firm North Castle Partners is seeking a buyer of Jenny Craig, DA Davidson analyst Linda Bolton Weiser said she sees "zero probability" that Medifast (MED) would acquire it and "almost zero probability" that Weight Watchers (WTW) would buy the company. Nutrisystem (NTRI), however, has already shown an interest in adding non-cannibalizing brands to its portfolio, making it the most likely buyer of Jenny Craig among the publicly-traded weight loss companies Weiser covers, she stated. Nutrisystem, which seems to have hit a wall in growing its biggest brand, may need a bold strategic move to provide visibility on growth and expansion, added the analyst. She keeps Buy ratings on Medifast and Weight Watchers and a Neutral rating on Nutrisystem shares.
CRY CryoLife
$33.64

-0.385 (-1.13%)

03/09/18
ADAM
03/09/18
NO CHANGE
Target $28
ADAM
Buy
CryoLife price target raised to $28 from $25 at Canaccord
Canaccord analyst Jason Mills raised his price target on CryoLife to $28 from $25 on expectations that solid execution will drive upside in 2018 and provide a set up for 2019-2020. The analyst cited the company's important pipeline projects and its integration of it JOTEC acquisition. Mills reiterated his Buy rating on CryoLife shares.
08/08/18
ADAM
08/08/18
NO CHANGE
Target $36
ADAM
Buy
CryoLife price target raised to $36 from $28 at Canaccord
Canaccord analyst Jason Mills raised his price target on CryoLife to $36 from $28 following its beat and raise Q2 results. The analyst noted its solid execution and improving underlying business trends. He also noted its acquisitions are tracking ahead of plan. Mills reiterated his Buy rating on CryoLife shares.
10/12/17
ADAM
10/12/17
NO CHANGE
Target $25
ADAM
Buy
CryoLife weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the selloff in CryoLife shares following its conference call about its acquisition of JOTEC is overdone. The analyst remains bullish about its prospects and sees several merits to the deal. He said it improves CryoLife's long-term growth prospects and margin profile. Mills reiterated his Buy rating and $25 price target on CryoLife shares.
10/11/17
LSCM
10/11/17
NO CHANGE
Target $26
LSCM
Buy
CryoLife price target raised to $26 from $23.50 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for CryoLife to $26 after the company announced the acquisition of JOTEC AG, a Germany based privately-held developer of technologically differentiated endovascular stent grafts. The deal expands CryoLife's addressable market and accelerates growth, O'Neil tells investors in a research note. The analyst affirms a Buy rating on the shares.

TODAY'S FREE FLY STORIES

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:49
10/22/18
10/22
16:49
10/22/18
16:49
Hot Stocks
FB Financial authorizes $50M common stock repurchase program »

FB Financial's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:48
10/22/18
10/22
16:48
10/22/18
16:48
Hot Stocks
FB Financial increases quarterly dividend 33% »

FB Financial Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

SSB

South State

$73.05

-1.975 (-2.63%)

16:48
10/22/18
10/22
16:48
10/22/18
16:48
Earnings
South State reports Q3 adjusted EPS $1.33, consensus $1.40 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVE

Universal Insurance

$47.72

0.72 (1.53%)

16:47
10/22/18
10/22
16:47
10/22/18
16:47
Hot Stocks
Universal Insurance announces expected financial impact from weather events »

Universal Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

HLT

Hilton

$70.17

-0.49 (-0.69%)

16:47
10/22/18
10/22
16:47
10/22/18
16:47
Initiation
Hilton initiated  »

Hilton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

SENS

Senseonics

$3.47

-0.14 (-3.88%)

16:46
10/22/18
10/22
16:46
10/22/18
16:46
Hot Stocks
Senseonics announces Aetna's positive coverage decision for Eversense »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

16:44
10/22/18
10/22
16:44
10/22/18
16:44
Hot Stocks
Chembio Diagnostics acquires opTricon GmbH for $5.5M in cash »

Chembioannounced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

HLT

Hilton

$70.17

-0.49 (-0.69%)

16:43
10/22/18
10/22
16:43
10/22/18
16:43
Initiation
Hilton initiated  »

Hilton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

H

Hyatt

$69.50

-0.18 (-0.26%)

16:43
10/22/18
10/22
16:43
10/22/18
16:43
Initiation
Hyatt initiated  »

Hyatt initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

MAR

Marriott

$111.49

-0.58 (-0.52%)

16:42
10/22/18
10/22
16:42
10/22/18
16:42
Initiation
Marriott initiated  »

Marriott initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

16:41
10/22/18
10/22
16:41
10/22/18
16:41
Earnings
Chembio Diagnostics sees Q3 revenue $9.2M-$9.5M, two estimate consensus $8.05M »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CIEN

Ciena

$30.97

0.23 (0.75%)

16:41
10/22/18
10/22
16:41
10/22/18
16:41
Initiation
Ciena initiated  »

Ciena resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:40
10/22/18
10/22
16:40
10/22/18
16:40
Earnings
HealthStream sees FY18 revenue growth of 6%-8%, consensus $229.26M »

"Consistent with our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:38
10/22/18
10/22
16:38
10/22/18
16:38
Hot Stocks
HealthStream CFO Gerard Hayden, Jr. resigns, Scott Roberts named interim CFO »

HealthStream's CFO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AFMD

Affimed N.V.

$3.15

-0.06 (-1.87%)

16:38
10/22/18
10/22
16:38
10/22/18
16:38
Syndicate
Breaking Syndicate news story on Affimed N.V. »

Affimed N.V. files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$102.58

-0.48 (-0.47%)

16:37
10/22/18
10/22
16:37
10/22/18
16:37
Hot Stocks
ResMed says it won German patent infringement case against Fisher & Paykel »

ResMed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

FN

Fabrinet

$44.71

-0.3 (-0.67%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Initiation
Fabrinet initiated  »

Fabrinet resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$186.64

0.47 (0.25%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Hot Stocks
Wex signs agreement to acquire Noventis »

WEX announced the signing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 26

    Nov

GOOG

Alphabet

$1,100.52

4.11 (0.37%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Hot Stocks
Google's YouTube investing $20M in education resources for 'EduTubers' »

YouTube is investing $20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Earnings
HealthStream reports Q3 EPS 9c, consensus 8c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WASH

Washington Trust

$52.03

-1.25 (-2.35%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Earnings
Washington Trust reports Q3 EPS $1.01, consensus 98c »

"Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FNSR

Finisar

$17.61

-0.19 (-1.07%)

16:34
10/22/18
10/22
16:34
10/22/18
16:34
Initiation
Finisar initiated  »

Finisar resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$45.76

-1.44 (-3.05%)

16:33
10/22/18
10/22
16:33
10/22/18
16:33
Earnings
Enterprise Financial reports Q3 core EPS 86c, consensus 89c »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:33
10/22/18
10/22
16:33
10/22/18
16:33
Hot Stocks
Hexcel backs FY18 free cash flow greater than $230M »

Backs FY18 accrual basis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:32
10/22/18
10/22
16:32
10/22/18
16:32
Earnings
Hexcel narrows FY18 adjusted EPS view to $2.99-$3.07 from 2.96-$3.10 »

FY18 consensus $3.03.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.